National Geographic Takes an Interest in Organs-on-Chips Research

Biomedical researchers at Cedars-Sinai Medical Center in Los Angeles, CA have caught the attention of National Geographic. The magazine published a special edition this month covering "The Future of Medicine" that highlights the innovative stem-cell science of Cedars-Sinai, showing how investigators there are seeking to use stem cells and organs-on-chips to tailor personalized medical treatments. The cover photo of the special issue features research being conducted at Cedars-Sinai in collaboration with Boston, MA-based Emulate, a startup developing a tissue-based technology designed to replicate human organ-level function that is used to model organs in healthy and diseased states. According to Cedars-Sinai, scientists can place copies of patients' own cells (created from their stem cells) inside transparent chips that are the size of AA batteries. Drugs then can be tested on the cells, to help doctors tailor treatment options to the individual patient. Using this technique, Cedars-Sinai has so far created functioning tissues of intestinal linings and spinal cords inside the chips, and more tissues are planned. Parkinson's disease, amyotrophic lateral sclerosis (ALS), ovarian cancer, and inflammatory bowel disease (which includes Crohn's and ulcerative colitis) are among the disorders being studied on the chip. The pioneering Patient-on-a-Chip program is a collaboration between the Cedars-Sinai Board of Governors Regenerative Medicine Institute, directed by Clive S...
Source: MDDI - Category: Medical Devices Authors: Tags: R & D Source Type: news

Related Links:

In this study, expression of CD47 was examined by immunostaining in colorectal cancer (CRC) and compared with the expression of CD44, which is a marker for cancer stem cells. In 95 cases of stage II –IV CRC, CD47 and CD44 showed overexpression in 82 and 80 cases, respectively. Both expression levels correlated with distant metastasis. Moreover, the expression of CD47 and CD44 in each case showed a significant correlation. In stage III cases, disease-free survival of cases showing high express ion of CD47 and CD44 was worse than that of the cases with low expression. Furthermore, 3 of the stage IV cases were administe...
Source: Pathobiology - Category: Pathology Source Type: research
Can a clinical trial in which treatment decisions are guided by intermediate patient outcomes be used in cancers?Annals of Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Publication date: Available online 24 May 2019Source: Brain, Behavior, and ImmunityAuthor(s): Donald M. Lamkin, Shreyesi Srivastava, Karen P. Bradshaw, Jenna E. Betz, Kevin B. Muy, Anna M. Wiese, Shelby K. Yee, Rebecca M. Waggoner, Jesusa M.G. Arevalo, Alexander J. Yoon, Kym F. Faull, Erica K. Sloan, Steve W. ColeAbstractAt the M2 terminal of the macrophage activation spectrum, expression of genes is regulated by transcription factors that include STAT6, CREB, and C/EBPβ. Signaling through β-adrenergic receptors drives M2 activation of macrophages, but little is known about the transcription factors involved. In ...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
Publication date: October 2019Source: Materials Science and Engineering: C, Volume 103Author(s): Murugesan Sathiya Deepika, Ramar Thangam, Thankaraj Salammal Sheena, R.T.V. Vimala, Srinivasan Sivasubramanian, Kulandaivel Jeganathan, Ramasamy ThirumuruganAbstractImproved therapeutic effects can be achieved by the delivery of combination of drugs through multifunctional cell targeted nanocarrier systems. The present investigation reports the preparation of Poly (D,L-lactic-co-glycolic acid) (PLGA) nanospheres loaded with the novel combination such as Rutin (R) and Benzamide (B) as drugs using water-oil-water (w/o/w) emulsion...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
(Joule Inc.) Despite potential for prolonging survival with treatment, one-third of patients with metastatic pancreatic cancer do not see a medical oncologist, and even more do not receive cancer-directed treatment, found new research published in CMAJ.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Source: Vascular Health and Risk Management - Category: Cardiology Tags: Breast Cancer: Targets and Therapy Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Academia | ALS | Brain | Cancer | Cancer & Oncology | Crohn's Disease | Gastroenterology | Harvard | Inflammatory Bowel Disease | Laboratory Medicine | Medical Devices | Molecular Biology | Neurology | Neuroscience | Ovarian Cancer | Ovaries | Parkinson's Disease | Science | Skin | Stem Cell Therapy | Stem Cells | Study | Ulcerative Colitis